Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-01-29
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00004862
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Lymphoma Trials Office
- Target Recruit Count
- 500
- Registration Number
- NCT00003578
- Locations
- 🇨🇿
Charles University Hospital, Prague (Praha), Czech Republic
🇬🇧City Hospital - Birmingham, Birmingham, England, United Kingdom
🇳🇴Norwegian Radium Hospital, Oslo, Norway
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3154
- Registration Number
- NCT00075725
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
- Conditions
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Eleos, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00074737
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸University of Miami Health Center, Miami, Florida, United States
🇺🇸North Shore University Hospital, Lake Success, New York, United States
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT00073957
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Fletcher Allen Health Care - Medical Center Campus, Burlington, Vermont, United States
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00074165
- Locations
- 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT00074178
- Locations
- 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00074191
- Locations
- 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2003-12-10
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 13
- Registration Number
- NCT00003729
- Locations
- 🇧🇪
Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels (Bruxelles), Belgium
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇧🇪Universitair Ziekenhuis Gent, Ghent (Gent), Belgium
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00003694
- Locations
- 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.